Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682962 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL10661597 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL7948406 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL2185989 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL8789697 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL375988 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL6266811 | 0.99 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL8790893 | 0.85 | KDM4E (0.44) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL3901295 | 0.85 | KDM4E (0.44) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL10663518 | 0.80 | HIF1A (0.46) | MAPTCYP3A4KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | claimed |
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | claimed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | claimed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | claimed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005090370-A1 | PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | claimed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| JP-58081794-A | — | — | None | — | — | JP | disclosed |
| EP-3546473-B1 | FLUORINATED CYCLIC [(2',5')P(3',5')P]-DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250213724-A1 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | CureVac SE (DE) | 2025-07-03 | — | — | US | disclosed |
| US-20250166176-A1 | METHODS AND MATERIALS FOR IMAGING ADIPOSE TISSUE | CELLSIGHT TECHNOLOGIES INC. (US) | 2025-05-22 | — | — | US | disclosed |
| WO-1992003568-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992001456-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| JP-S5881794-A | PREPARATION OF 9-BETA-D-ARABINOFURANOSYLGUANINE | YAMASA SHOYU CO LTD | 1983-05-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | TYMP, MTAP, NTPCR | PNP 5/4885MAPT 3972/4885CYP3A4 3987/4885 |
| US-20250213724-A1 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | RNASE1, RNMT, TRDMT1 | PNP 436/4885MAPT 2972/4885CYP3A4 4885/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | PNP 159/4885MAPT 4812/4885CYP3A4 180/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | PNP 14/4885MAPT 3773/4885CYP3A4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.